Google's Flo Deal Is a Strategy Announcement, Not an Earnings Event
Google Health announced Monday a multi-year partnership with Flo, the menstrual- and ovulation-tracking app, wrapped in a strategic investment from Google Health. The press release sells scale: more than 80 million women use the app monthly and over half a billion have downloaded it since launch. The instinctive read is that Google is pulling the leader in women's health into its orbit.
Missing from the announcement is the one number that would make that read true: no price. "Strategic investment" is not an acquisition, and Flo remains an independent company. The substance ships only later - users won't be able to link Flo to Google Health until early 2027, when Fitbit-measured sleep, heart rate, heart-rate variability, skin temperature and respiratory rate begin syncing into Flo's cycle predictions. This is a roadmap, not a delivered product.
Read the scale number the way it deserves to be read: the user base is the raw input, and revenue per user is the output. The output is thin. Flo is a freemium subscription business - Flo Premium costs $59.99 a year - but the overwhelming majority of its roughly 80 million monthly users pay nothing. Even attributing its entire reported 2025 subscription revenue of roughly $275 million across that base yields about $3.50 per user per year. Google's interest is in raising that quotient: use continuous Fitbit signals and life-stage AI coaching to convert free users into paying ones, and to sell the wearable that collects the data. It is not chasing more free users.
The same window shows the pattern. The Fitbit Edge, a $179.99 tracker positioned between the screenless Fitbit Air and the Pixel Watch, went on preorder Monday, and a separate deal will pull more than 160 lab results into Google Health. All of it serves one outcome - convincing people the Google Health subscription is worth paying for, a recurring-services platform assembled against Apple's rival health stack rather than a single winning app.
The heavy scaffolding around consent should be read as admission as much as commitment. The announcement stresses that no data moves without permission, that shared data will never be used for advertising and never sold. That language is not novelty; it is the price of handling the exact data class that has already gotten both companies sued. Flo previously resolved an FTC matter over allegations it shared users' health information with third-party data analytics providers despite promising that information would remain private. And in a class-action settlement announced this month, $59.5 million was distributed, with Google paying $48 million of it, over allegations that Flo's app embedded third-party code exposing menstrual-cycle and pregnancy data to those firms without consent - allegations all sides denied. A "consent-first" women's health partnership with the company that just paid $48 million of the $59.5 million settlement over women's health data is, whatever its merits, defensively constructed.
For an investor the arithmetic is simpler than the strategy: there is no Flo stock. Flo is private, last priced at a $1.2 billion valuation in its 2024 Series C. The only public way to own this story is through Alphabet, where the health push is immaterial - Ainvest data puts Alphabet's market cap near $4.3 trillion. Alphabet is not being re-rated because it took an undisclosed stake in a women's health app.
What would change that judgment is adoption, and adoption is the deciding observable this announcement cannot prove. Google needs to show that a year from now, linking Fitbit to Flo and Google Health actually lifts wearable sales and subscription uptake; otherwise the partnership is a footnote. Read it today as a small, real experiment in whether health data can become recurring services - cheap enough that failure costs Alphabet almost nothing. Watch the Fitbit and Google Health subscription numbers next year; ignore the press release now.
